These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
228 related items for PubMed ID: 27271767
1. Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study. Gong IY, Verma S, Yan AT, Ko DT, Earle CC, Tomlinson GA, Trudeau ME, Krahn MD, Krzyzanowska MK, Brezden-Masley CB, Gavura S, Peacock S, Chan KK. Breast Cancer Res Treat; 2016 Jun; 157(3):535-44. PubMed ID: 27271767 [Abstract] [Full Text] [Related]
2. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C, Herceptin Adjuvant (HERA) Trial Study Team. Lancet; 2017 Mar 25; 389(10075):1195-1205. PubMed ID: 28215665 [Abstract] [Full Text] [Related]
3. Impact of Stopping Trastuzumab in Early Breast Cancer: A Population-Based Study in Ontario, Canada. Rushton M, Lima I, Tuna M, Johnson C, Ivars J, Pritchard K, Hawken S, Dent S. J Natl Cancer Inst; 2020 Dec 14; 112(12):1222-1230. PubMed ID: 32343801 [Abstract] [Full Text] [Related]
8. The Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional Analysis. Wu YY, Huang TC, Tsai TN, Chen JH, Dai MS, Chang PY, Ho CL, Ye RH, Chung TR, Chen YC, Chao TY. PLoS One; 2016 Dec 14; 11(3):e0151112. PubMed ID: 26953588 [Abstract] [Full Text] [Related]
11. Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab. Lee CK, Kim SS, Park S, Kim C, Heo SJ, Lim JS, Kim H, Kim HS, Rha SY, Chung HC, Park S, Jung M. Oncotarget; 2017 May 09; 8(19):31169-31179. PubMed ID: 28415714 [Abstract] [Full Text] [Related]
12. Trastuzumab-related cardiotoxicity in patients with nonlimiting cardiac comorbidity. Martinello R, Becco P, Vici P, Airoldi M, Del Mastro L, Garrone O, Barone C, Pizzuti L, D'Alonzo A, Bellini E, Milani A, Bonzano A, Montemurro F. Breast J; 2019 May 09; 25(3):444-449. PubMed ID: 30932296 [Abstract] [Full Text] [Related]
19. Evaluation of 1-Year vs Shorter Durations of Adjuvant Trastuzumab Among Patients With Early Breast Cancer: An Individual Participant Data and Trial-Level Meta-analysis. Gulia S, Kannan S, Badwe R, Gupta S. JAMA Netw Open; 2020 Aug 03; 3(8):e2011777. PubMed ID: 32833018 [Abstract] [Full Text] [Related]
20. A pooled analysis of the cardiac events in the trastuzumab adjuvant trials. de Azambuja E, Ponde N, Procter M, Rastogi P, Cecchini RS, Lambertini M, Ballman K, Aspitia AM, Zardavas D, Roca L, Gelber RD, Piccart-Gebhart M, Suter T. Breast Cancer Res Treat; 2020 Jan 03; 179(1):161-171. PubMed ID: 31605311 [Abstract] [Full Text] [Related] Page: [Next] [New Search]